Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Myasthenia Gravis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    66 result(s) found for: Myasthenia Gravis. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2018-002133-37 Sponsor Protocol Number: ARGX-113-1705 Start Date*: 2019-06-06
    Sponsor Name:argenx BVBA
    Full Title: A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis having Generalized...
    Medical condition: Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    21.1 10029205 - Nervous system disorders 10028423 Myasthenia gravis-like syndrome LLT
    20.0 100000004859 10071942 Myasthenia gravis and related conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) CZ (Completed) DE (Completed) DK (Completed) BE (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000895-40 Sponsor Protocol Number: BETA-MG-01 Start Date*: 2019-03-28
    Sponsor Name:Aarhus University Hospital
    Full Title: Beta-agonist Efficacy and Tolerability as Adjuvant therapy in Myasthenia Gravis
    Medical condition: Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001544-21 Sponsor Protocol Number: MG2012PREP Start Date*: 2012-11-07
    Sponsor Name:Vall d'Hebron Institut de Recerca (VHIR)
    Full Title: Intravenous immunoglobulin for preparing myasthenia gravis patients for thymectomy and other surgical procedures preventing myasthenic crisis.
    Medical condition: Myasthenia gravis
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003230-20 Sponsor Protocol Number: MG0007 Start Date*: 2020-11-30
    Sponsor Name:UCB Biopharma SRL
    Full Title: An Open-Label Extension Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis
    Medical condition: Generalized myasthenia gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) CZ (Completed) FR (Completed) PL (Completed) HU (Completed) DK (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000968-18 Sponsor Protocol Number: MG0003 Start Date*: 2019-09-06
    Sponsor Name:UCB Biopharma SRL
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis.
    Medical condition: Generalized myasthenia gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) PL (Completed) DE (Completed) HU (Completed) CZ (Completed) BE (Completed) ES (Restarted) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002698-36 Sponsor Protocol Number: MG0002 Start Date*: 2017-02-09
    Sponsor Name:UCB Biopharma SPRL
    Full Title: A Multicenter, Randomized, Investigator- and Subject-Blind, Placebo-Controlled, Treatment Sequence Study Evaluating the Safety, Tolerability, and Efficacy of UCB7665 in Subjects with Moderate to Se...
    Medical condition: Moderate to severe myasthenia gravis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) CZ (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-000596-34 Sponsor Protocol Number: WX17798 Start Date*: 2005-05-19
    Sponsor Name:F.Hoffmann-La Roche Ltd.
    Full Title: A prospective, randomized, double-blind, placebo controlled, parallel group, multicenter, 36-weeks trial to assess the efficacy and safety of adjunct mycophenolate mofetil (MMF) to maintain or impr...
    Medical condition: Myasthenia gravis
    Disease: Version SOC Term Classification Code Term Level
    7.1 10028417 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-002817-37 Sponsor Protocol Number: PIX200701 Start Date*: 2008-07-29
    Sponsor Name:ISTITUTO NEUROLOGICO "CARLO BESTA"
    Full Title: A PHASE II, PLACEBO CONTROLLED, DOSE FINDING PILOT STUDY OF PIXANTRONE EFFICACY ADMINISTERED INTRAVENOUSLY IN PATIENTS AFFECTED WITH MYASTHENIA GRAVIS
    Medical condition: Patients affected with MG showing clinically meaningful improvement after therapeutic plasmapheresis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028417 Myasthenia gravis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004086-38 Sponsor Protocol Number: ARGX-113-2002 Start Date*: 2021-08-06
    Sponsor Name:argenx BV
    Full Title: A Long-Term, Single-Arm, Open-label, Multicenter Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myast...
    Medical condition: Generalized Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) BE (Completed) NL (Completed) IT (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-000460-21 Sponsor Protocol Number: ALXN1720-MG-301 Start Date*: 2022-11-18
    Sponsor Name:Alexion Pharmaceuticals, Inc
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis.
    Medical condition: Generalized Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) AT (Trial now transitioned) HU (Prematurely Ended) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-000343-28 Sponsor Protocol Number: WX18411 Start Date*: 2005-12-19
    Sponsor Name:Aspreva Pharmaceuticals Corporation
    Full Title: An optional continuation of double-blind treatment for subjects who have achieved good symptom control with stable prednisone dosing and who have completed Protocol WX17798 (A prospective, randomiz...
    Medical condition: Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004018-25 Sponsor Protocol Number: MSK-002 Start Date*: 2018-02-22
    Sponsor Name:CATALYST PHARMACEUTICALS INC.
    Full Title: A Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients with MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Pos...
    Medical condition: MuSK antibody positive myasthenia gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000969-21 Sponsor Protocol Number: MG0004 Start Date*: 2019-12-04
    Sponsor Name:UCB Biopharma SPRL
    Full Title: A Randomized, Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
    Medical condition: Generalized myasthenia gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (GB - no longer in EU/EEA) DK (Completed) BE (Completed) DE (Completed) ES (Restarted) CZ (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005619-35 Sponsor Protocol Number: REFINE2020 Start Date*: 2021-06-07
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: SINGLE-CELL DEEP PHENOTYPING OF B LYMPHOCYTES TO PERSONALIZE IMMUNOTHERAPY IN PATIENTS WITH MYASTHENIA GRAVIS: CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF RITXUXIMAB IN GENERALIZED ACHR-A...
    Medical condition: Generalized AChR-antibody positive Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000097-35 Sponsor Protocol Number: CCFZ533X2204 Start Date*: 2015-09-02
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, double-blind, placebo-controlled, parallel group study to preliminarily evaluate the safety, tolerability, pharmacokinetics and efficacy of CFZ533 in patients with moder...
    Medical condition: Acquired myasthenia gravis (MG) is an autoimmune disease that leads to fluctuating muscle weakness and fatigue. In the most common cases, muscle weakness is caused by circulating antibodies that bi...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-001384-37 Sponsor Protocol Number: ECU-MG-303 Start Date*: 2020-10-07
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Eculizumab in Pediatric Patients with Refractory Generalized Myasthenia Gravis (gMG)
    Medical condition: Refractory Generalized Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2022-003870-21 Sponsor Protocol Number: MG0020 Start Date*: 2023-07-25
    Sponsor Name:UCB Biopharma SRL
    Full Title: An open-label, crossover study to evaluate rozanolixizumab self-administration by study participants with generalized Myasthenia Gravis
    Medical condition: Generalized Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004777-14 Sponsor Protocol Number: MSK-003 Start Date*: 2018-06-05
    Sponsor Name:CATALYST PHARMACEUTICALS INC.
    Full Title: Long term safety study of amifampridine phosphate in patients with MuSK antibody positive and AChR antibody positive myasthenia gravis patients
    Medical condition: MuSK antibody and AChR antibody positive myasthenia gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-000323-27 Sponsor Protocol Number: CV-0003 Start Date*: 2017-08-03
    Sponsor Name:CuraVac Europe SA
    Full Title: A Multi-center, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Subcutaneous Injections of the Myasthenia Gravis Active Targeted Immunotherapy CV-MG0...
    Medical condition: Myasthenia Gravis (MG) is a chronic neuromuscular disorder characterized by weakness and fatigability of skeletal muscles. The underlying defect is a decrease in the number of available acetylcho...
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000949-14 Sponsor Protocol Number: VIB0551.P3.S1 Start Date*: 2020-11-16
    Sponsor Name:Viela Bio, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED PHASE 3 STUDY WITH OPEN-LABEL PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF INEBILIZUMAB IN ADULTS WITH MYASTHENIA GRAVIS
    Medical condition: Myasthenia Gravis which is either due to acetylcholine receptor antibodies (AChR) or muscle specific kinase antibodies (MuSK).
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DK (Prematurely Ended) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 07:42:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA